Navigation Links
Lixte Biotechnology Holdings, Inc. Awarded Grant Under Qualifying Therapeutic Discovery Project from the U. S. Government
Date:3/2/2011

EAST SETAUKET, N.Y., March 2, 2011 /PRNewswire/ -- Lixte Biotechnology Holdings (OTC: LIXT) announced today that the company has received a $244,479.25 grant under the Qualifying Therapeutic Discovery Project (QTDP).  This grant was awarded to further development and commercialization of Lixte's novel anti-cancer compound LB-100.  The QTDP program was included as part of the Patient Protection and Affordable Care Act of 2010 to encourage development of new therapies to prevent, diagnose, and treat acute and chronic diseases.  The selection process took into consideration the potential of projects to reduce long-term healthcare costs in the United States or significantly advance the goal of curing cancer over the next 30 years.  The selections were made jointly by the Department of Health and Human Services and the Treasury Department.  

"We are extremely pleased to have qualified for this grant," said Dr. John Kovach, founder and president of Lixte. "The funds will be used as part of our effort to complete pre-clinical studies and submit an IND to the FDA to bring our novel compound LB-100 to Phase I clinical trial. LB-100 represents a new type of anti-cancer drug, which we hope will improve treatments for several different types of human cancers for which more effective therapies are urgently needed."

About Lixte Biotechnology Holdings, Inc:Lixte Biotechnology Holdings, Inc. is a cancer therapeutics company. Founded as a biomarker-diagnostics company in 2005, Lixte primary focus is discovery of new chemotherapy drugs based on targeting molecular abnormalities of common human cancers critical to their survival.

Forward-Looking StatementsThis announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regardin
'/>"/>

SOURCE Lixte Biotechnology Holdings
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Lixte Biotechnology Holdings, Inc. Announces the Approval of a Collaboration with the National Cancer Institute for Clinical Evaluation of its Lead Anti-Cancer Compound, LB-100.
2. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
3. Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
4. Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
5. Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
6. Pharma ChemOutsourcing Targets BioNJ, PA Bio, MassBio, BayBio, SoCalBio, and NY Biotechnology Association Member Companies for September 2011 Show in New Jersey
7. Reportlinker Adds Global Biotechnology Instrumentation Industry
8. NASDAQ Removes TLCR From Biotechnology Index Pending FTC Decision on Grifols Acquisition
9. Reportlinker Adds Global Agricultural Biotechnology Industry
10. Champions Biotechnology Awarded $1.46 million in Grants
11. Goodwin Biotechnology Announces Signing New Biopharmaceutical Development & Manufacturing Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  Actavis plc (NYSE: ... Company has received a complete response letter from ... its New Drug Application (NDA) for the fixed-dose ... treatment of hypertension.   Photo - ... disappointed in the receipt of a complete response ...
(Date:12/24/2014)... CHENGDU, China, Dec. 24, 2014 /PRNewswire/  -- Tianyin ... a pharmaceutical company that specializes in the patented ... and active pharmaceutical ingredients (API) released unaudited preliminary ... year 2015. Fiscal Year 2015 Ended ... was $9.7 million compared with $14.7 million in ...
(Date:12/24/2014)... 2014 Soligenix, Inc. (OTCQB: SNGX) (Soligenix ... products that address unmet medical needs in the ... that on December 24, 2014 it closed its ... Company raised approximately $2.3 million in gross proceeds ... net proceeds from the offering to fund its ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3
... Technologies, Incorporated (IDEV), an innovative leader in the development ... another step in the implementation of its strategy to ... vascular disease with the addition of two longer stents ... the newly introduced 180mm and 200mm stents occurred in ...
... Shionogi-ViiV Healthcare LLC today announced the start ... once-daily, unboosted investigational integrase inhibitor, S/GSK1349572 (,572). The ... includes two studies (SPRING-2 and SAILING) that will ... but integrase-naive patients. "Progression of ...
Cached Medicine Technology:IDEV Technologies Launches Additional Products in Europe 2Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor 2Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor 3Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor 4Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor 5
(Date:12/25/2014)... 25, 2014 (HealthDay News) -- The risk of burns ... so you need to be extra cautious, an expert ... see a significant increase in patients coming in with ... Suffolk County Volunteer Firefighters Burn Center of Stony Brook ... be full of joy, but if not careful, could ...
(Date:12/25/2014)... AngelWeddingDress.com tries its best to translate the experience ... business has introduced its new collection of 2015 prom ... The new prom outfits are guaranteed to contain the ... are specially designed for 2015. Anyone who wants to ... its website before Jan. 26, 2015, the deadline of ...
(Date:12/25/2014)... North Carolina (PRWEB) December 25, 2014 ... North Carolina Retirement Community, recently showed their generous ... girls of the Catawba County Parenting Network- Grandparents ... the 10 children gathered around the largest Christmas ... to open presents purchased by residents of the ...
(Date:12/24/2014)... 25, 2014 Over 700 toys, that’s ... local communities. That is 700 smiling little faces this ... Additionally over $6000 in monetary donations was given to ... of the expenses they incur through the year. Some ... A Child's Haven , Shrine's Children's Hospitals, Toys ...
(Date:12/24/2014)... York (PRWEB) December 24, 2014 Risperdal ... in a mass tort litigation currently underway in Pennsylvania’s ... As of December 24, 2014, court documents indicate ... on behalf of individuals who developed gynecomastia (male breast ... Data from the Court indicates that this represents an ...
Breaking Medicine News(10 mins):Health News:Don't Let Burns Mar Your Holidays 2Health News:Angelweddingdress 2015 Prom Dresses Online Now 2Health News:Retirement Community Residents Make Impact During Holiday Season 2Health News:AlignLife Donates Over 700 Toys This Year 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4
... CRT replacements for MRI, CT, US, NM, X-ray, ... is now available from Medical Displays for Less. ... equipment ROI and lower replacement costs with new ... to adapt and display the signals from GE, ...
... also air on the Big Ten NetworkUNIVERSITY PARK, Pa., May ... "Emotionless warriors" and thought scans of detainees may not be ... ethical ramifications of these innovations? Find out by watching the ... State . This new series, hosted ...
... ARLINGTON, Va., May 19 The National Alliance ... "Exemplary Psychiatrists" at the American Psychiatric Association (APA) ... to honor 41 psychiatrists from across the country ... mental illness," said NAMI executive director Michael Fitzpatrick. ...
... , , TUESDAY, May 19 (HealthDay News) -- A mother,s ... own health but on the respiratory health of her ... at an increased risk of asthma if the mother ... the department of prevention and health services research at ...
... now available online to read, share, or purchaseNEW ... ), a global leader in electronic content ... of Physicians (ACP) has launched its e-book portal ... easy-to-implement, cost-effective, self-service solution that allows publishers to ...
... Present Clinical Data at, ... Upcoming Scientific Meeting -,LAVAL, QC, May ... ) today announced the publication of Extended Release Trazodone in Major ... issue of the journal Psychiatry (Edgemont) (Volume 6, Number 5) ( ...
Cached Medicine News:Health News:Universal CRT Replacement Gives New Life to Medical Equipment with Analog Video 2Health News:Universal CRT Replacement Gives New Life to Medical Equipment with Analog Video 3Health News:WPSU Debuts New Series; 1st Show Tackles Neuroscience and the Military 2Health News:NAMI Applauds America's Exemplary Psychiatrists 2Health News:NAMI Applauds America's Exemplary Psychiatrists 3Health News:Overweight Moms More Likely to Have Asthmatic Kids 2Health News:Overweight Moms More Likely to Have Asthmatic Kids 3Health News:American College of Physicians Chooses iPublishCentral to Launch its e-Book Strategy 2Health News:Results of phase III study on Labopharm's novel antidepressant published in Psychiatry (Edgemont) Journal 2Health News:Results of phase III study on Labopharm's novel antidepressant published in Psychiatry (Edgemont) Journal 3Health News:Results of phase III study on Labopharm's novel antidepressant published in Psychiatry (Edgemont) Journal 4
... were developed in surgeon's desire to have ... an instrument with the strength to maneuver ... the bending or breaking. Arthrotek Hand Instruments ... to the surgeon's hand. This new generation ...
... Meniscal Stapler XLS consists of a resorbable ... the staple. The staple is used in ... The staple is made of a resorbable ... and glycolic acids. Polylactic/polyglycolic acid copolymer degrades ...
... BTA stat Test is an ... qualitative detection of bladder tumor ... with bladder cancer. This test ... aid in the management of ...
... in a bottle becomes preservative-free on ... into oxygen and water on eye ... with mild to moderate dryness or ... treatment. Now you can have the ...
Medicine Products: